Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Chenye Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6800-1649; OpenAlex author ID A5064776321. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 9

  1. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  2. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Co-author DOI 10.1002/advs.202302498↗
  3. Retraction Note: MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-023-48852-5↗
  4. Overexpression of miR-135b-5p promotes unfavorable clinical characteristics and poor prognosis via the repression of SFRP4 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.19150↗
  5. microRNA-454 shows anti-angiogenic and anti-metastatic activity in pancreatic ductal adenocarcinoma by targeting LRP6. First author PMID 28123855↗
  6. MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep22793↗
  7. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Co-author DOI 10.1097/mpa.0000000000000501↗
  8. Associations of GSTM1 and GSTT1 polymorphisms with pancreatic cancer risk: evidence from a meta-analysis. Co-author DOI 10.1007/s13277-012-0598-6↗
  9. HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression. Co-author DOI 10.1159/000354460↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenhui Lou · 4 shared papers, 2013–2025 · strength 0.48
  2. Liang Liu · 2 shared papers, 2023–2025 · strength 0.35
  3. Ning Pu · 2 shared papers, 2023–2025 · strength 0.35
  4. Huaxiang Xu · 2 shared papers, 2023–2025 · strength 0.35
  5. Hanlin Yin · 2 shared papers, 2023–2025 · strength 0.35
  6. Qiangda Chen · 2 shared papers, 2023–2025 · strength 0.35
  7. Ding-Fang Cai · 2 shared papers, 2016–2023 · strength 0.29
  8. Wei Wei · 2 shared papers, 2016–2023 · strength 0.29
  9. Dansong Wang · 2 shared papers, 2016–2023 · strength 0.29
  10. Yue Fan · 4 shared papers, 2013–2017 · strength 0.27
  11. Yue Fan · 1 shared paper, 2023 · strength 0.22
  12. Sami Shoucair · 1 shared paper, 2025 · strength 0.19
  13. Shanshan Gao · 1 shared paper, 2025 · strength 0.19
  14. Lei Zhang · 1 shared paper, 2025 · strength 0.19
  15. Joseph R. Habib · 1 shared paper, 2025 · strength 0.19
  16. Taochen He · 1 shared paper, 2025 · strength 0.19
  17. Michael Goggins · 1 shared paper, 2025 · strength 0.19
  18. Yun Jin · 1 shared paper, 2025 · strength 0.19
  19. Tiantao Kuang · 2 shared papers, 2017 · strength 0.17
  20. Lei Zhang · 1 shared paper, 2023 · strength 0.16
  21. Wenquan Wang · 1 shared paper, 2023 · strength 0.16
  22. Jun Yu · 1 shared paper, 2023 · strength 0.16
  23. Wenchuan Wu · 1 shared paper, 2023 · strength 0.16
  24. Xu Han · 2 shared papers, 2016–2017 · strength 0.14
  25. Junjie Zhao · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.